CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Revenues:
License and milestone fees	$ 25,678	$ 429	$ 38,845	$ 1,362
Royalty revenue	2,335		4,388
Research and development support	1,922	2,036	3,912	3,413
Clinical materials revenue	125	147	133	1,928
Total revenues	30,060	2,612	47,278	6,703
Operating Expenses:
Research and development	20,862	21,656	42,891	45,356
General and administrative	5,447	5,464	11,973	11,103
Total operating expenses	26,309	27,120	54,864	56,459
Income (loss) from operations	3,751	(24,508)	(7,586)	(49,756)
Other income, net	62	115	172	171
Net income (loss)	3,813	(24,393)	(7,414)	(49,585)
Basic and diluted net income (loss) per common share (in dollars per share)	$ 0.04	$ (0.29)	$ (0.09)	$ (0.59)
Basic weighted average common shares outstanding (in shares)	85,431	84,147	85,221	83,748
Dilutive impact of potential common shares (in shares)	1,845
Diluted weighted average common shares outstanding (in shares)	87,276	84,147	85,221	83,748
Total comprehensive income (loss)	$ 3,813	$ (24,393)	$ (7,414)	$ (49,585)